Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma.
Bottom Line: BACH2, a B cell-specific transcriptional repressor, plays a significant role in B cell maturation.There were no significant differences between the two groups with regard to clinical characteristics and outcomes.In cases with high BACH2 expression in GCB and non-GCB groups, the 3-year overall survival (OS) rate was significantly shorter than that with low expression (71.7% vs 91.3%, P = 0.0256).
Affiliation: Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.Show MeSH
Related in: MedlinePlus
Mentions: All patients were treated with rituximab-containing chemotherapy (Table 1). Overall treatment response was good and resulted in a 3-year OS rate of 80.8% and a 3-year PFS rate of 71.0%. After three years following diagnosis, there were no cases of relapse or death from any causes. Survival outcome is shown in Table 1 and Figure 2. There were no differences in survival outcome; however, more relapsed cases were confirmed in the non-GCB group, which could result in relatively short PFS. In cases with high BACH2-expression, 3-year OS rate was significantly shorter than that with low expression (71.7% vs 91.3%, P = 0.0256). The 3-year PFS was also shorter than that with low expression, although it was not significant (62.5% vs 80.3%, P = 0.0681).
Affiliation: Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.